Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT ID: NCT06290102

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-16

Study Completion Date

2024-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objectives of this study are:

* To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma
* To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI)
* To compare the PK profiles of ABS between the 2 different strengths of TEV-56248

The secondary objective is:

• To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The planned duration for this trial is approximately 1.5 to 3 months. The trial includes a 14-day screening period, 3 treatment periods (2 days each), and a follow up visit 7 days after end of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence ABC

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Sequence BCA

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Sequence CAB

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Sequence ACB

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Sequence BAC

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Sequence CBA

Group Type EXPERIMENTAL

TEV-56248

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Fp MDPI

Intervention Type DRUG

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TEV-56248

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Intervention Type DRUG

Fp MDPI

Pharmaceutical form: Dry powder

Route of administration: Oral inhalation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

- fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI) - fluticasone propionate multidose dry powder inhaler

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has a diagnosis of asthma as defined by the Global Initiative for Asthma guidelines (GINA 2023), which has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in asthma medication) for at least 30 days before the Screening Visit
* Has persistent asthma, with a forced expiratory value (FEV1) that is greater than or equal to 80% of the value predicted for age, height, sex, and race at the Screening Visit
* Demonstrate acceptable inhalation technique with the training inhaler
* Able to stop (as judged by the Investigator) his or her rescue medication, for approximately 6 hours before the Screening Visit and for approximately 4 hours before training sessions in periods 1-3
* Has body mass index (BMI) within the 3rd and 97th percentiles for the participant's age and gender. The participant must have a weight of ≥18 kilograms (kg)
* Able to achieve a peak inspiratory flow (PIF) rate of at least 60 liters per minute (L/min) on an inhaler training device

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria

* Participant has a history of a life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures
* Has participated as a randomized participant in any investigational drug trial within 30 days (starting from the final follow-up visit of that trial) preceding the Screening Visit or plans to participate in another investigational drug trial at any time during this trial
* Known hypersensitivity to any corticosteroid, albuterol, or any of the ingredients in the investigational medicinal product
* Asthma exacerbation requiring systemic corticosteroids within 30 days of the Screening Visit, or has had any hospitalization for asthma within 2 months of the Screening Visit

NOTE- Additional criteria apply, please contact the investigator for more information
Minimum Eligible Age

4 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Teva Medical Expert, MD

Role: STUDY_DIRECTOR

Teva Branded Pharmaceutical Products R&D, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Teva Investigational Site 12010

Mobile, Alabama, United States

Site Status

Teva Investigational Site 12003

Long Beach, California, United States

Site Status

Teva Investigational Site 12007

Miami, Florida, United States

Site Status

Teva Investigational Site 12005

Miami, Florida, United States

Site Status

Teva Investigational Site 12002

Miami, Florida, United States

Site Status

Teva Investigational Site 12008

Lafayette, Louisiana, United States

Site Status

Teva Investigational Site 12011

Columbia, Missouri, United States

Site Status

Teva Investigational Site 12012

Oklahoma City, Oklahoma, United States

Site Status

Teva Investigational Site 12001

Boerne, Texas, United States

Site Status

Teva Investigational Site 12009

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TV56248-RES-10204

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Advair Pediatric Once-Daily
NCT00920959 COMPLETED PHASE3